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Alzheimer’s disease pathology (AD) originates in the
hippocampus and subsequently spreads to tempo-
ral, parietal, and prefrontal association cortices in a
relatively stereotyped progression. Current evidence
attributes this orderly progression to transneuronal
transmission of misfolded proteins along the projec-
tion pathways of affected neurons. A network diffu-
sion model was recently proposed to mathematically
predict disease topography resulting from trans-
neuronal transmission on the brain’s connectivity
network. Here, we use this model to predict future
patterns of regional atrophy and metabolism from
baseline regional patterns of 418 subjects. The
model accurately predicts end-of-study regional
atrophy and metabolism starting from baseline
data, with significantly higher correlation strength
than given by the baseline statistics directly. The
model’s rate parameter encapsulates overall atrophy
progression rate; group analysis revealed this rate to
depend on diagnosis as well as baseline cerebrospi-
nal fluid (CSF) biomarker levels. This work helps vali-
date the model as a prognostic tool for Alzheimer’s
disease assessment.INTRODUCTION
Alzheimer’s disease (AD) is an amyloid-facilitated tauopathy
(Braak et al., 2000) whose origin and subsequent advance within
the brain is well characterized: the disease begins in the mesial
temporal lobe, an event accompanied by the accumulation of
misfolded b-amyloid and tau proteins, and thence progresses
along fiber pathways. Histopathological evidence of this highly
stereotyped progression has come to be known as the Braak
model (Braak and Braak, 1996): neurofibrillary tau tangles areCfirst found in entorhinal cortex and hippocampus (stages I–II),
then spread into the amygdala and basolateral temporal lobe
(stages III–IV), followed by isocortical association areas (stages
V–VI). Morphological changes accompanying this pathological
progression are clearly visible on MRI, especially from cross-
sectional and longitudinal morphometric mapping (Fischl et al.,
2002; Klauschen et al., 2009; Smith et al., 2004; Wu et al.,
2007). Longitudinal studies (Apostolova and Thompson, 2008;
Apostolova et al., 2007; Thompson et al., 2003; Whitwell et al.,
2007) confirm that progression follows vulnerable fiber pathways
rather than spatial proximity (Englund et al., 1988; Kuczynski
et al., 2010; Villain et al., 2008), closely mirroring Braak patholog-
ical stages (Whitwell et al., 2007).
Until recently, the causative mechanisms for this networked
spread were thought to be passive, including secondary Waller-
ian degeneration, disconnection, loss of signaling, axonal reac-
tion, and postsynaptic dendrite retraction (Seeley et al., 2009).
The latest evidence, however, favors a transneuronal ‘‘prion-
like’’ mechanism (Frost and Diamond, 2010; Jucker and Walker,
2013), whereby implicated proteins misfold, trigger misfolding
of adjacent same-species proteins, and thereupon cascade
along neuronal pathways via transsynaptic or transneuronal
spread (Clavaguera et al., 2009; Frost et al., 2009; Jucker and
Walker, 2011, 2013; Palop and Mucke, 2010). Exogenous seed-
ing of pathogenic proteins in the hippocampus caused remote
pathology in connected regions (Clavaguera et al., 2009; Jucker
and Walker, 2013). Seeded templating of misfolded protein
species can therefore be thought of as the causative ‘‘propa-
gating’’ event, and other observed phenotypes—hypometabo-
lism, atrophy, and cognitive dysfunction—result from the
pathology.
Recently, transneuronal transmission was mathematically
modeled in our laboratory (Raj et al., 2012) by a diffusive mech-
anism mediated by and restricted to the brain’s connectivity
network, and the resulting topography of the disease was math-
ematically deduced. The network was obtained using diffusion
MRI-derived healthy ‘‘connectomes’’ (Lo et al., 2010). Intrigu-
ingly, the macroscopic consequences of diffusive prion-like
propagation (the network diffusion or ND model) on healthyell Reports 10, 359–369, January 20, 2015 ª2015 The Authors 359
Table 1. Demographic Characteristics of the Study Cohorts
Gender Young Control (Age) ADNI Control (Age) ADNI AD (Age) ADNI MCI (Age)
Female 29 (23.0 ± 5.8) 37 (75.8 ± 5.8) 39 (74.8 ± 6.9) 49 (74.9 ± 8.2)
Male 44 (23.2 ± 4.3) 58 (73.6 ± 5.4) 60 (76.5 ± 7.2) 102 (75.5 ± 6.7)networks recapitulated patterns of atrophy in various dementias.
Specifically, the model predicted spatially distinct ‘‘eigen-
modes,’’ which mirrored disjoint brain regions known to be
selectively targeted by different dementias (Buckner et al.,
2005; Seeley et al., 2009). This mathematical reformulation of
descriptive neuropathological observations into a deterministic
encapsulation of neurodegenerative progression opens the pos-
sibility of dementia prognostication.
The goal of this study is to develop the theoretical model of Raj
et al. (2012) into a clinically useful computational biomarker with
the ability to predict future patterns of atrophy in susceptible in-
dividuals. Implicit in this work is that baseline atrophy is sufficient
to give future predictions. Although motivated by stereotyped
Braak-type progression, individual subjects’ model predictions
do not rely on a priori monolithic Braak staging assumptions.
We are aware of no other existing tool that can predict future
topography of AD atrophy and metabolism in individuals. There
are clear applications of our biomarker in prognosis and as a
monitoring tool in clinical trials.
To assess our biomarker’s relative utility, we compare it
against quantitative models representing the alternative hy-
pothesis that growth of degeneration in different regions are in-
dependent processes that are not transmitted via white matter
connections. We chose two established hypotheses: (1) a sig-
moid model of disease progression (Jack et al., 2010), which
was verified using cerebrospinal fluid (CSF) amyloid scans
(Jack et al., 2013), whereby every brain region undergoes a
separate but temporally well-defined degeneration character-
ized by slow initial growth rate, peak intermediate growth,
and a declining eventual growth rate reflecting saturation
effects; and (2) an exponential model, where highly affected
regions undergo faster degeneration separately and indepen-
dently from other regions. The exponential model also
describes activity-dependent degeneration, whereby lifetime
neuronal activity, rather than network transmission, is thought
to govern degeneration and rapidity (Buckner et al., 2005; Grei-
cius et al., 2004).
RESULTS
The study cohort consists of all Alzheimer’s Disease Neuroimag-
ing Initiative (ADNI) subjects who had two to four longitudinal
MRI and fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) scans; their demographics are summarized in Table 1.
Where appropriate, results are stratified by diagnosis: mild
cognitive impaired (MCI) converters, MCI nonconverters, and
AD. The outcome of the analysis pipeline on this data procedure
was a regional atrophy/metabolism number for each subject,
evaluated at 90 regions covering the entire cerebral gray matter,
with no gaps, taken from a neuroanatomically accurate parcel-
lated brain atlas.360 Cell Reports 10, 359–369, January 20, 2015 ª2015 The AuthorsTesting the Regionally Varying Relationship between
Baseline and Rate of Change
Scatterplots of the empirical relationship between baseline atro-
phy/metabolism and their rate of change are shown in Figure S1.
Each dot represents a parcellated gray matter (GM) structure of
each subject, where the x axis represents baseline value and
the y axis the slope. There is no simple relationship between
baseline atrophy/hypometabolism and its slope that fits all re-
gions and subjects. Neither the straight line (exponential, green)
nor parabola (sigmoid, cyan) captures this relationship fully,
althoughboth capture portionsof the data. TheNDmodel predic-
tion (red, middle panel) appears to successfully cover the
atrophy-slope plane. A topographic rendering of this relationship
is shown in Figure S2 (top: regional baseline t-statistic of all
patients’ FDG-derived regional hypometabolism [left], its rate of
change [middle], and the network diffusion model-predicted
rate of change [right]). The slope in hypometabolism is not simply
proportional to baseline; there is general agreement in temporo-
parietal regions, but not in frontal and occipital regions. Black ar-
rows point to specific structures that are discordant. Conversely,
in mesial temporal structures, the rate of change is less than
would be predicted by linearly extrapolating the baseline map.
In these discordant structures, the network diffusion model ap-
pears to be a better predictor of slope than the baseline map.
Next, we assess the accuracy of each model in predicting the
regional rate of change from baseline in both MRI atrophy and
FDG-PET-derived hypometabolism (Figure 1). The correlation
between the measured and predicted slope of the entire
MCI+AD cohort gave the following values: atrophy: R = 0.72
(exponential model), R = 0.68 (sigmoid), R = 0.85 (network diffu-
sion); FDG hypometabolism: R = 0.48 (exponential), R = 0.40
(sigmoid), R = 0.75 (network diffusion). While all three models
considered here capture to some extent the slope of atrophy/
hypometabolism, the NDmodel achieves the highest correlation.
Fisher’s R-to-z transform gave a significant difference in the re-
ported R achieved by the proposed model and both competing
models (p < 102).
Predicting Future Patterns of Atrophy and
Hypometabolism
Validation of the predictive ability of our model is contained in
scatterplots in Figure 2. Each point corresponds to a single re-
gion in a single subject. Both MRI-derived atrophy and FDG-
PET-derived hypometabolism are shown. Measured regional
baseline statistics already exhibit a strong and significant rela-
tionship to atrophy/metabolism at end of study (first and third
columns), expectedly, since drastic progression within 2–4 years
is unlikely. Correlation strength is generally higher for hypome-
tabolism than for atrophy, probably due to lower noise and
fewer artifact-inducing processing steps in FDG-PET images.
Interestingly, a significant subset of regional atrophy data appear
Figure 1. Correlation between Measured
and Predicted Atrophy/Metabolism Slope
Exponential model (linear relationship, left), sig-
moid model (middle), and network diffusion model
(right). Pearson’s R and p are shown alongside.
Top panel shows MRI atrophy and the bottom
FDG-PET hypometabolism data. In both cases,
the network diffusion model gives stronger
correlations than the other two models. See also
Figure S1.to stray from the diagonal (first column), implying that localized
relationships are not sufficient to capture disease dynamics. A
closer investigation of these discordant regions (see the Supple-
mental Experimental Procedures and Figure S2, bottom) re-
vealed them to occur mostly in the frontal and occipital cortex
in MCI converters. These regions are typically involved in late,
but not early, stages, distal but connected to vulnerable tempor-
oparietal areas, hence ‘‘next-in-line’’ for future progression.
The correlation strength R (Table 2) is significantly improved in
all diagnoses by adding the NDmodel, and the above discordant
‘‘off-diagonal’’ regions were brought back onto the diagonal.
Fisher’s R-to-z transform indicates these improvements to be
highly significant, implying that the model is adding strong
predictive power that cannot be explained by the baseline
data alone. The model greatly reduces unexplained variance
(1  R2), for instance in MCI converters, where it goes from
0.24 using baseline alone, to 0.08 using the ND model, consti-
tuting a net improvement of 300%. Note that these data are
group-level summaries of individual subjects’ predictions, using
each individual’s baseline scan. Hence, while these numbers
amply characterize the capability of the prognostic biomarker,
theydonot indicatepredictionperformance for a given individual.
Robustness Analysis
To characterize the robustness of our putative biomarker against
noise and intersubject variability, increasing amounts of inde-
pendent Gaussian noise were added to the reference connec-
tomes and the confidence interval (CI) of the R statistic in Table 2
was estimated usingMonte Carlo simulations with 100 trials (Fig-
ure S6A). Predicted R appears tolerant to moderate levels of
connectome noise. Second, the effect of intersubject variability
in the R statistic was explored via bootstrap analysis by repeat-
edly resampling 1,000 times from the ADNI cohort (see the Sup-
plemental Experimental Procedures and Figure S6B). The 95%
CI of predicted R statistic is listed in Table 2. Clearly, our results
have almost zero bias and are highly robust to intersubject vari-Cell Reports 10, 359–369ability and well within the range expected
from sampling errors. Interestingly, con-
nectome noise-induced variability in R is
actually less than that due to variability
in patients.
Example Future Predictions of
Atrophy and Hypometabolism
Some visually illustrated anecdotal exam-
ples of future progression are presented,going beyond the 2- to 4-year timewindowof ADNI data. Figure 3
verifies that the group statistics of AD subjects, the best-charac-
terized and stereotyped group, follows expected progression.
The spheres are proportional to the t-statistic of MRI atrophy
after logistic transform and color-coded by lobe (frontal = blue,
parietal = purple, occipital = green, temporal = red, and subcor-
tical = yellow). The ND model correctly recapitulates the classic
Alzheimer progression from mesial temporal structures to
parietal and finally frontal areas. The rate of progression param-
eter was estimated by empirical fitting to individual subject
data as described earlier, but in order to minimize risk of overfit-
ting, the time-since-onset parameter was fitted to each diag-
nostic group rather than to individuals. FDG hypometabolism
results (Figure 3B) are similar. Next, we show six examples
drawn from individual subjects from all three diagnosis cate-
gories, selected via visual inspection as typifying the most
commonmodes of behavior we observed in each disease group.
Figures 3C and 3D show two representative AD examples,
whose classic temporal-dominant atrophy pattern remains
steady over extrapolated time scales as it progressively grows
more severe.
Figure 4 shows two example MCI nonconverters. The left
panel depicts regional MRI-derived atrophy at baseline with
respect to ADNI healthy controls, after logistic transform to
convert Z scores to positive atrophy values between 0 and 1.
The next two panels show the network diffusion model predic-
tion from baseline atrophy, extrapolated to 5 years and 10 years
out. The top case exhibits classic MCI topography with hippo-
campal involvement, but model extrapolation does not indicate
subsequent extrahippocampal spread or temporal involvement,
consistent with MCI-nonconverter status. The bottom case is an
interesting variant of the nonconverter case, with prominent
widespread atrophy at baseline in the frontal cortex. However,
extrapolated atrophy patterns stay within the frontal areas and
subsequently spread to parietal, but not temporal, regions—in
consonance with MCI-nonconverter diagnosis., January 20, 2015 ª2015 The Authors 361
Figure 2. Validation of the Predictive Power of the Network Diffusion Model
Columns 1 and 2 pertain toMRI-derived atrophy data and columns 3 and 4 to FDG-PET-derived hypometabolism data. The ADNI cohort is stratified by diagnosis:
MCI nonconverters (top row), MCI converters (middle), and AD (bottom). The relationship between baseline regional atrophy and atrophy at end of study is strong
and significant in all cases, including measured data (first and third columns) and model predictions (second and fourth columns). However, the correlation
strength is greatly and significantly improved in all diagnosis types by the network diffusion model. See also Figure S2 and the Supplemental Experimental
Procedures.Figure 5 shows two examples of MCI converters, one of which
(bottom row) exhibits the classic AD pattern of progression
within and outward from the temporal lobe. Baseline atrophy is
overall mild, but the extrapolated patterns show the classic
progression fromMCI to AD. Specifically, the recruitment of tem-
poral and subcortical regions, which are associated with mem-
ory-related cognitive dysfunction, increases prominently. The
top case also exhibits prominent and early temporal involve-
ment, but longitudinal predictions are more prominent in frontal
and parietal regions. This case is consistent with current diag-
nosis of MCI converter, but worsening frontoparietal atrophy
may be expected.
Results of Subject-Wise Fitting of Model Parameters
The fitted model parameters—time between onset and baseline
scan tpostonset and the rate constant of network diffusion b—are
quite variable across subjects. The distribution of b, shown in
Figure S3, categorized by diagnosis, appears to follow an expo-
nential distribution, whose parameters we fit using MATLAB’s
expfit() function and display in Table 3. Since the 95% CIs per-
taining to the three groups do not overlap, it may be concluded362 Cell Reports 10, 359–369, January 20, 2015 ª2015 The Authorsthat the rate parameters of the three groups are statistically sig-
nificant and come from different distributions. Notably, a clear
order emerges, such that b(MCI  N) z b(MCI  C) < b(AD),
with the mean rate parameter of AD group almost twice as large
as the MCI groups, whether it is fitted to MRI atrophy or FDG hy-
pometabolism data, an intuitive and expected result. Figure S3
shows that postonset time is widely distributed, without a
discernible difference between groups.
Given that baseline CSF biomarkers of amyloid deposition
(Ab  42), tau (tau and p-tau) and their ratio ((Ab  42)/tau), are
known to be correlated with diagnosis (Da et al., 2014; Dickerson
and Wolk, 2013; Roe et al., 2011; Shaw et al., 2011), we next
investigated whether these biomarkers impart a similar influence
on the rate constant and postonset time. Scatterplots depicting
these potential influences are shown in Figure S4, along with
Pearson correlation statistics. These results suggest little inde-
pendent role for CSF biomarkers, after accounting for the infor-
mation contained in the baseline image, in determining the rate
of progression or time since onset. Given that CSF biomarkers
are known to have a threshold effect, whereby their effect is im-
parted only at pathological levels (Fjell et al., 2010), we next













MCI-N atrophy 0.85 0.97 [0.951, 0.98] 0.28 0.059 p < 104
MCI-C atrophy 0.87 0.96 [0.94, 0.974] 0.24 0.078 p < 104
AD atrophy 0.89 0.96 [0.933, 0.975] 0.21 0.078 p < 104
MCI-N FDG 0.92 0.96 [0.95, 0.968] 0.15 0.078 p < 102
MCI-C FDG 0.89 0.93 [0.926, 0.951] 0.21 0.14 p < 102
AD FDG 0.88 0.95 [0.944, 0.964] 0.23 0.10 p < 104
MCI-N, MCI nonconverter; MCI-C, MIC converter.dichotomize the ADNI subjects into two groups: pathological
baseline CSF Ab  42 (<192 pg/ml) and nonpathological
(>192 pg/ml, bottom). The histogram of b in Figure S5 and distri-
bution statistics in Table 3 demonstrate that b, our marker of the
rate of progression, is significantly higher in the pathological
versus nonpathological group. We repeated this analysis for
genotypic dichotomization into APOE-ε4 allele noncarriers and
carriers (Figure S5, right). There was no difference between the
two groups when fitting b to MRI atrophy, but a significant differ-
ence was observed when fitting to FDG-PET, where exponential




The proposed predictive model captures diffusive interneuronal
propagation enacted on the brain’s connectivity network, an
approach that was previously shown to recapitulate classic
topographic patterns of common dementias (Raj et al., 2012).
Although the concepts on which this model is based are known,
our main contribution is that we were able to formalize andmath-
ematically encode existing understanding and employ them
toward the goal of predicting future progression in individual
subjects. By turning different competing descriptive hypotheses
into testable predictions, we were able to statistically compare
them. We found strong statistical evidence in favor of the
network diffusion model.
The major findings of this study were as follows. First, using
baseline MRI volumetrics and PET-based glucose hypometabo-
lism, the model predicted future atrophy/metabolism patterns of
AD and MCI subjects drawn from the ADNI database. Second,
the model captured the regionally varying baseline and slope
relationship accurately and to a larger extent than alternate local-
ized growth models, viz sigmoid, and exponential growth. Third,
an investigation of the fitted rate of progression in individuals
showed group differences between MCI and AD. The role of
CSF biomarkers in determining the rate of progression is re-
vealed only after dichotomizing the CSF data. Evidence for the
role of APOE allele status is mixed. Since the proposed predic-
tive model works on individual subjects, it is a computational
prognostic biomarker. Group-level summary statistics are pre-
sented here to characterize this biomarker, but the underlying
data come from individual subjects’ predictions. A thoroughCrobustness analysis via Monte Carlo simulations and bootstrap
analysis demonstrated the predictor performance to be insensi-
tive to connectome noise and intersubject variability. Each result
is discussed below in the context of current literature.
Capturing the Relationship between Regional Atrophy
and Its Rate of Change
The regional baseline/slope relationship provides an effective
way of testing the validity of progression models, since in the 2-
to 4-year window of observation, the progression in the ADNI
cohort may be considered roughly linear. It is known from
morphometric AD studies that the baseline/rate relationship is
complex (Jack et al., 2009); atrophied regions appeared to evolve
differently depending on disease stage (Whitwell et al., 2007), and
atrophy ratewas reported tohavea regionally varying relationship
withAb deposition (Tosun et al., 2011). Our result (Figures S1 and
S2) also suggests a regionally varyingbaseline/slope relationship.
Baseline and change values are in good agreement in classically
vulnerable temporoparietal regions, but not in frontal and occipi-
tal regions, which give the ‘‘off-diagonal’’ effect seen in Figure 2.
However, these regions are strongly connected to already-
affected regions, hence ‘‘next-in-line’’ for future changes accord-
ing to the transneuronal transmission hypothesis. Thus, without
considering network connectivity, these regions would arguably
be prone to underestimation as sites of future change. Examining
the correlation strength between measured atrophy slope and
model prediction (Figure 1), the networkmodel is strongly predic-
tive of slope (R = 0.85 for atrophy slope, R = 0.75 for hypometab-
olismslope). A nonnetworkedmodel of localized spread,whether
exponential (predicting a linear relationship) or sigmoid (parabolic
relationship), also predicts the slope, but not as well.
Comments on Alternative Localized Growth Models
The localized growth models were obtained by mathematically
encoding existing hypotheses. We allowed different regions
and subjects to be placed at different points along the sig-
moid/exponential curves, since they may be at different stages
of degeneration. In Jack et al. (2013), a similar strategy of placing
different subjects (although not regions) at different points along
the sigmoid curve demonstrated that long nonlinear sigmoid or
exponential dynamics over the duration of the disease can be
fit to narrow time windows exhibiting only linear trends. The
choice of these simple local growth models in favor of nonlocal
statistical models, e.g., projections to ‘‘AD-signature’’ regionsell Reports 10, 359–369, January 20, 2015 ª2015 The Authors 363
Figure 3. ‘‘Glass Brain’’ Illustrations of
Regional Statistics of AD Subjects from
the ADNI Cohort
The spheres are proportional to effect size,
and color-coded by lobe: frontal = blue,
parietal = purple, occipital = green, temporal = red,
and subcortical = yellow.
(A and B) Group regional atrophy (A) and meta-
bolism (B) statistics of all AD subjects are shown.
Left: regional t-statistic at baseline with respect to
ADNI healthy controls, after logistic transform.
Network diffusion model prediction based on
baseline atrophy, extrapolated to 5 years out
(middle) and 10 years out (right). Our extrapola-
tions recapitulate the classic pattern of AD pro-
gression, from mesial temporal to parietal and
finally frontal structures.
(C and D) Two illustrative AD examples. In both
cases, the classic AD pattern of atrophy is seen at
baseline as well as at predicted future time points,
albeit with increasing severity.(Da et al., 2014), wasmotivated by our goal of assessing the spe-
cific role of the network in determining the dynamics of AD.
Agreement with Prior Longitudinal Imaging Studies
MRI atrophy is strongly correlated with cognitive impairment and
its topographic distribution correlates well with Braak staging at
autopsy (Jack et al., 2010; Whitwell et al., 2009). FDG-PET is
correlated with impaired synaptic function (Rocher et al.,
2003), cognitive impairment, and postmortem AD diagnosis
(Hoffman et al., 2000). Apostolova et al. elegantly described
the patterns of AD progression from longitudinal MRI, showing
stereotyped spread of atrophy from temporal to parietal and
frontal regions (Apostolova and Thompson, 2008; Apostolova
et al., 2007). Morphological changes in MCI patients measured
using voxel-based morphometry followed a classic Braak
pattern of progression, starting from anterior medial temporal re-
gions at 3 years prior to conversion, spreading to nearby tempo-
ral and parietal cortices, and at AD diagnosis encompassing the
classic temporoparietofrontal AD pattern (Whitwell et al., 2007).
The ND model’s predictions (Equation 5) are in good agreement364 Cell Reports 10, 359–369, January 20, 2015 ª2015 The Authorswith these longitudinal observations. The
MCI-converter examples (Figure 4) reca-
pitulate almost perfectly the progression
described in Whitwell et al. (2007). Simi-
larly, the AD cases (Figure 3) are in good
agreement with the topographic evolu-
tion shown in Apostolova and Thompson
(2008) and Whitwell et al. (2007). Of note,
the ND model gives more accurate pre-
diction than linear local growth reflected
by baseline correlations.
The Role of Focal Origin,
Syndromic, Pathological, and
Genotypic Characteristics
We do not explicitly rely on any kind of
selective vulnerability or origination site,e.g., entorhinal cortex and hippocampus (Braak and Braak,
1992; Braak and Del Tredici, 2012; Braak et al., 2000), this being
implicit in the baseline scan. Origination site might be dictated by
selective vulnerability due to various stressors (Braak et al.,
2000; Palop et al., 2006; Saxena and Caroni, 2011; Seeley
et al., 2009) or innate gene expression in origination sites (Goel
et al., 2014). Presented data suggest that even if origination sites
are anatomically or architectonically determined, the subse-
quent spread and eventual topographic fate of AD pathology
are likely determined by network topology.
The puzzling dissociation between imaging-based neurode-
generative patterns and the distribution of AD-causing pathology
(tau and Ab) is well known (Jack et al., 2010). MRI atrophy and
FDG-PET binding are closely associated with cognitive deficits
and tangles, but not withAb deposition (Jack et al., 2010; Landau
et al., 2012; Murray et al., 2011; Robinson et al., 2011). Three
distinct topographical patterns were reported in AD—classical
(75%), limbic predominant (14%), and hippocampus sparing
(11%)—reflecting heterogeneous origination and spread sites
(Murray et al., 2011). Approximately 20%–40% of cognitively
Figure 4. Glass Brain Illustrations of Two
Example MCI Nonconverters from the
ADNI Cohort
The spheres are proportional to effect size and
color-coded by lobe: frontal = blue, parietal =
purple, occipital = green, temporal = red, subcor-
tical = yellow. Left: regional Z score of MRI-derived
atrophy at baseline with respect to ADNI healthy
controls, after logistic transform. Network diffu-
sion model prediction based on baseline atrophy,
extrapolated to 5 years out (middle) and 10 years
out (right). Neither case progresses into prominent
temporal involvement.normal elderly people have significant Ab plaque deposition
(Jack et al., 2010). Given these dissociations, the utility of a
single-spread model in describing AD topography might be
doubted. However, the model’s function is not to capture a spe-
cific pathologic agent like amyloid or tau but to model progres-
sion starting at baseline markers of degeneration, howsoever
they may have arisen.
Interestingly, we found a strong dependence of the subject-
wise fitted rate of progression parameter b on subjects’
diagnostic status but no correlation between baseline CSF bio-
markers and rate of progression. A strong group difference
was however seen when the subjects are dichotomized into
high- or low-biomarker regimes (Table 3). Numerous prior re-
ports show a definite association between CSF biomarker levels
and risk of AD. It could be that our fitting procedure or CSF
biomarker levels or both are noisy. Since the subject’s morpho-
metric information is already built into the estimate of b via Equa-
tion 6, our result might simply imply that CSF biomarkers lack
incremental power to predict rate of progression, beyond what
is explained by imaging. This is in line with converging under-
standing based on the early deposition and subsequent plateau-
ing of amyloid (Villemagne et al., 2013), that while CSF
biomarkers are good predictors of conversion risk, neurodegen-
erative markers like MRI are more sensitive predictors of current
disease state and its rate of decline (Da et al., 2014; Dickerson
and Wolk, 2013; Fjell and Walhovd, 2011; Jack et al., 2009;
Vemuri et al., 2009). Our dichotomized CSF results support this
interpretation, such that CSF biomarker levels appear to exert
an effect on rate of progression only beyond the pathologic
threshold (Fjell et al., 2010; Mattsson et al., 2014; Schott et al.,
2010). The effect of APOE status on rate of decline b was mixed:
nonsignificant for MRI atrophy but significant for FDG-PET;
potentially, this could be due to the generally higher signal to
noise ratio observed in FDG data.
Clinical and Diagnostic Implications
These results provide support to the network diffusion model as
a prognostic aid to the clinician, allowing them to predict whatCell Reports 10, 359–369the patient’s neuroanatomic state will be
at any given point in the future. Knowl-
edge of what the future holds can
empower patients and allow informed
choices regarding lifestyle, therapeutic,
and nontherapeutic interventions. TheNDmodel could potentially be used to enhance cohort stratifica-
tion and monitoring accuracy in large-scale clinical trials and
thus improve statistical power at a lower cost. By allowing
extrapolation of baseline state regardless of syndromic classifi-
cation, these data could present an opportunity to disentangle
and disambiguate AD subtypes in a clinical setting. Future neu-
roradiologists might plausibly eschew uncertain syndromic cate-
gorization in favor of quantitative models of topographical
patterning of future disease states as early markers of disease.
Cases of mixed dementia could also benefit, where classical re-
gion-based atrophy descriptors might prove unsatisfactory.
Limitations
This is a first-order, linear, parsimonious model of diffusive
spread that assumes static networks, even though both atrophy
and the network must dynamically evolve. However, these
nonlinear effects are difficult to capture analytically and can
only be accessed via numerical finite difference computa-
tions—a topic of future work. The model only considers the
long-range transmission of proteopathic carriers and not their
local ‘‘leaking’’ via synapses and dendrites, because local cir-
cuitry is neither observable by noninvasive tractography nor
necessary for modeling large-scale macroscopic patterns.
Technical limitations of the volumetric and tractography pro-
cessing pipelines include HARDI spatial and angular resolution,
coregistration errors, low test-retest reliability of volumetric
data, and the distance bias inherent in tractography. These
issues are even more problematic in longitudinal analysis, but
we believe this high-powered study is able to withstand these
challenges. Although the model enables long-term projections,
its validation was limited to public (ADNI) data sets of rather nar-
row time span (2–4 years), precluding long-term longitudinal
follow-up. One of the most attractive aspects of our model, its
ability to capture nonlinear trajectories of disease, is poorly
tested by these data. We hope that future work will address
this gap. Finally, healthy reference rather than individual patients’
connectomes were used for individual prediction to avoid indi-
vidual variability and noise and because the ADNI database did, January 20, 2015 ª2015 The Authors 365
Figure 5. Glass Brain Illustration of the Pre-
dictive Ability of the Model on Two Example
MCI Converters, with Mild but Early Tempo-
ral Involvement, Progressing to the Classic
AD-type Topography with Prominent Tem-
poral Involvementnot contain diffusion MRI scans. However, variability in connec-
tomes appears to exert only minor influence on our model (see
Figures S5 and S6 of Raj et al., 2012); hence, our conclusions





Axial T1-weighted fast spoiled gradient-echo scans (TE = 1.5 ms, TR = 6.3 ms,
TI = 400 ms, 15 flip angle, 230 3 230 3 156 isotropic 1 mm voxels) and
high angular resolution diffusion imaging (HARDI) data (55 directions, b =
1,000 s/mm2, 72 1.8-mm-thick interleaved slices, 0.85943 0.8594 mm planar
resolution) were acquired on a 3T GE Signa EXCITE scanner from 73 fully con-
sented young healthy volunteers under a previous institutional review board-
approved study (Kuceyeski et al., 2013).
Age-Matched Normal, AD, and MCI Cohorts
Data used in this article were obtained from the ADNI database (http://adni.
loni.usc.edu). Launched in 2003 as a $60million, 5-year public-private partner-
ship, ADNI aims to test whether serial MRI, PET, other biological markers, and
clinical and neuropsychological assessment can be combined to measure the
progression of MCI and early AD. More details of ADNI methodology are in the
Supplemental Experimental Procedures. Diagnosis is established by ADNI at
each longitudinal time point based on natural history and cognitive assess-
ment. We further classified MCI subjects as MCI converter or MCI non-
converter, depending on whether their baseline diagnosis changed to AD at
follow up. Volumetric 3D MPRAGE or equivalent T1-weighted 1.5 T images
are available at ADNI, with 1.25 3 1.25 3 1.2 mm resolution; acquisition pa-
rameters are reported elsewhere (Mueller et al., 2005). For FDG-PET scans,
subjects were injected with 5 mCi F18-FDG 30min prior to FDG-PET scanning
and six 5 min frames were acquired by the ADNI consortium.
Image Processing
In our laboratory, ADNI PET frames were coregistered to eliminate the effects
of motion, an average image was generated, and then intensity normalized
such that the average of voxels within the subject’s mask is exactly one. The
average image was nonlinearly warped into MNI152 space using SPM5 soft-
ware toolbox, with 2 mm isotropic voxels and 79 3 95 3 69 (in x y z) matrix
size. Regional FDG uptake was normalized by the subject’s cerebellar refer-
ence uptake. GM brain regions were parcellated from all subjects’ T1-MRI
scans using an atlas-based parcellation scheme (SPM from Klauschen
et al., 2009 and IBASPM from Iturria-Medina et al., 2007) to extract 116 regions366 Cell Reports 10, 359–369, January 20, 2015 ª2015 The Authorsof interest (ROIs). The T1 image tissue segmenta-
tions in 1-mm isotropic MNI space were used to
create a normalized atlas, and the FDG PET im-
ages were resliced to matching resolution in
SPM. The MNI atlas was then applied to the re-
sliced FDG to calculate signal mean for each of
the 116 regions. Twenty-six cerebellar regions
were removed, giving regional statistics on 90 re-
gions covering the cerebrum with no gaps.
Connectomes from healthy HARDI scans were
extracted using previously described methodol-
ogy (Kuceyeski et al., 2013), which included
Q-ball reconstruction followed by probabilistic
tractography seeded at the gray-white interfacevoxels of the parcellated ROIs, with 1,000 streamlines drawn per seed voxel.
Each streamline is assigned a probability score (Iturria-Medina et al., 2008),
and connection strength is estimated by summing the probabilities of the
streamlines terminating in the two regions. A combined connectivity matrix,
C, is then obtained by averaging across healthy subjects.
Model Validation against ADNI Data
Normalized atrophy of each ADNI subject was computed in terms of regional Z
score of volume with respect to age-matched ADNI normal, such that for sub-
ject k and brain region i,
zkðiÞ= tkðiÞ  mhðiÞ
shðiÞ ;
where mh(i),sh(i) are the ADNI healthy controls’ mean and SD of volume of re-
gion i. Since only the highest positive values denote atrophy, the Z scores




ezk ðiÞ=s + ezk ðiÞ=s
;
where theparameters controls thesteepnessof the logistic function.Analogous
formulas govern regional hypometabolism statistics obtained from FDG-PET
maps. These statistics are vectorized over all regions to givemeasured atrophy
vectors ck for all subjects k. All regional statistics, whether measured or pre-
dicted, were mapped within the brain using a ‘‘glass brain’’ rendering using in
house open source MATLAB Brainography toolkit (LoCastro et al., 2014).
Development of a Predictive Network Diffusion Model of Dementia
The connectivity matrices above define a network or graph G= fV;Eg whose
nodes vi˛V represent gray matter structures and edges ei;j˛E represent fiber
connectivity. The burden of disease-causing proteinopathic agent is repre-
sented by the vector xðtÞ= fxðv; tÞ; v˛Vg at time t at each node. It was pro-
posed in (Raj et al., 2012) that dementia progression into this network in a




=  bHxðtÞ; (Equation 1)





ci; j for isj and ct; js0P
t; j0 :ei; j˛E
ct;j for i = j
0 otherwise
:
Table 3. Exponential Distribution Parameter l of Subject-Wise b






MCI-N 0.025* [0.022, 0.030] 0.022* [0.019, 0.026]
MCI-C 0.020* [0.016, 0.025] 0.024* [0.020, 0.029]
AD 0.037 [0.030, 0.045] 0.046 [0.038, 0.056]
Ab  42 > 192 pg/ml 0.012* [0.009, 0.016] 0.022* [0.017, 0.029]
Ab  42 < 192 pg/ml 0.027* [0.023, 0.032] 0.036* [0.031, 0.043]
APOE-ε4 noncarriers 0.030 [0.026, 0.035] 0.029* [0.025, 0.035]
APOE-ε4 carriers 0.030 [0.026, 0.035] 0.045* [0.039, 0.053]
Significance of MCI versus AD group, and low- versus high-CSF amyloid
and APOE carrier versus noncarriers groups, are denoted by * when their
95% confidence intervals do not overlap. See also Figures S3–S5.
MCI-N, MCI nonconverter; MCI-C, MIC converter.This is the graph equivalent of the Laplacian diffusion operator DxbV2x. Since
all brain regions are not the same size, each row and column of the Laplacian is
normalized by their sums. This diffusion model captures transneuronal propa-
gation as a connectivity rather than distance-based process, enacted via
active axonal transport followed by membrane or exocytotic processes into
extracellular space. Fiber length does not enter this model, since there is no
evidence that axonal transport efficiency is dependent on fiber length.
From matrix algebra, Equation 1 is satisfied by
xðtÞ= ebHt x0; (Equation 2)
where x0 is the initial pattern of the disease process, on which the term e
bHt
acts essentially as a spatial and temporal blurring operator. We therefore call
ebHt the diffusion kernel, and Equation 2 is interpreted as the impulse
response function of the network. Since the above requires matrix exponenti-
ation, it is solved via the eigendecomposition of the network Laplacian H into a
number of eigenmodes into which the diffusive process becomes trapped, and







ui : (Equation 3)
The eigenvalues li of the Laplacian H are in the interval [0,2], with a single
0 eigenvalue and a small number of near-zero eigenvalues. Most eigenmodes
ui correspond to large eigenvalues that quickly decay due to exponentiation,
leaving only the small eigenmodes that remain operative.
Relationship to Atrophy/Metabolism
The measurable phenotype (regional atrophy in MRI, hypometabolism in FDG-
PET) in region k is assumed to be the consequence of the accumulation of pa-





On the whole brain, this givesFðtÞ= R t0 xðtÞ dt. These results are summarized
from (Raj et al., 2012), and below we derive results capturing the temporal dy-
namics of the model.
Prediction of Future Atrophy and Metabolism






















CAUyx0:CThe last expression is necessitated by the fact that l1 = 0, which gives
lim
l1/0
ð1 el1btÞ=l1b= t. Note also that early in the disease,
lim
t/0
Uð1=bÞL1ðI eLbtÞUyx0 = tx0. For tractability, we assume that this rela-
tionship hold in all subjects, such that F(tpostonset) z tpostonsetx0, where
tpostonset is the time elapsed between disease onset and baseline scan.















CA UyFbaseline: (Equation 5)
We perform prediction of future atrophy and hypometabolism in patients using
Equation 5.
Relationship between Atrophy and Its Rate of Change
From the above, we have
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Thus, the network diffusionmodel deterministically predicts that the atrophy or
hypometabolism at any time point and their rate of change are related via the
matrix ~HðbtÞ.
Nonnetworked Models: Sigmoid and Exponential
The exponential growth model is mathematically given by F(t) f exp(t/a)F0
and the sigmoid by F(t) f 1/(exp(t/a) + exp((t/a)))F0. However, it is known
that different brain regions and different subjects experience atrophy, hypo-
metabolism, and pathology at different time points; hence, we allow different
subjects and brain regions to be placed at different points along the above















 t  tj;k
a
F0j;k ðsigmoidÞ;
where tj,k is the time since disease onset of region j in subject k. Thus, all sub-
jects and regions are hypothesized to fall on the same growth curve with a
single scale parameter a, albeit different temporal location tj,k. Note that neither
nonnetworked model formula involves connectivity, since they assume local-
ized progression.
The corresponding relationship predicted by the exponential model is, by
definition, dFj,k/dtfFj,k(t). It can be shown that the sigmoid model would pre-
dict thatdFj,k(t)/dtfFj,k(t)(max(Fj,k)Fj,k(t))—an analytic result that appears to
have been reproduced statistically in an earlier thorough investigation of longi-
tudinal behavior of amyloid PETdata (Jack et al., 2013). In that paper, aB-spline
fitting procedure revealed that an ‘‘inverted U’’-shaped curve best described
the relationship between amyloid burden at baseline and its rate of change.
The quadratic expression above would predict exactly this curve shape.
Estimating Unknown Model Parameters
For prediction of individual subjects, two unknown parameters must be esti-
mated for each subject: the time between onset and baseline scan tpostonset
and the rate constant of network diffusion b. We do this by fitting these param-
eters to measured regional slope data, using the baseline-slope relationship
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where corr(,,,) refers to the Pearson correlation coefficient between two vec-
tors, c is the measured atrophy or hypometabolism of the given subject, and
Dc/Dt is the measured slope. Then, the rate constant b is given by the best












CSF biomarker levels of amyloid, tau, and p-tau were obtained from the ADNI
database, and subsequently, their prediction ability of ND model parameters
was investigated using Pearson correlation. The statistics of CSF biomarkers
was also investigated within dichotomized groups (based on diagnosis, APOE
status, and baseline CSF biomarker level), as described in Results. Histograms
were fitted to exponential distributions usingMATLAB’s expfit() function and its
mean parameter obtained, as enumerated in Figures S3–S5.
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